Table 3. Prior studies of predictive markers of 5-fluoruracil and gemcitabine efficacy from randomized adjuvant trials.

First author	Year	Tumor	Treatment	Marker	Result summary
Ohrling39	2013	Colorectal	5-FU	MSI and TS	5-FU beneficial for ↓MSI and ↑TS
Farrell29,*	2012	Pancreas	Gem	CDA	Gem less toxic with CDA variant SNP
Sinicrope41	2011	Colorectal	5-FU	MSI	5-FU beneficial for ↑MSI
Manayakorn28,*	2010	Pancreas	5-FU	H3K4me2, H3K9me2	5-FU ineffective with low histone modification
Farrell25,*	2009	Pancreas	Gem	hENT1	Gem beneficial for ↑hENT1
Colozza36	2005	Breast	C, M, 5-FU	HER2	5-FU ineffective for ↑HER2
Buess35	2004	Colorectal	5-FU, MMC	STRAP	Chemotherapy ineffective with STRAP amplification
Ribic40	2003	Colorectal	5-FU	MSI	5-FU beneficial for ↓MSI
Edler37	2002	Colorectal	5-FU	TS	5-FU beneficial for ↑TS
Mild38	2002	Colorectal	5-FU, MMC	DCR3	5-FU ineffective for DCR3 amplification
Ahnen32	1998	Colorectal	5-FU	KRAS and P53	5-FU beneficial for WT KRAS and ↓P53
Augenlicht34	1997	Colorectal	5-FU	MYC	5-FU beneficial for low MYC amplification

*From RTOG 9704. Additional abbs: 5-FU, 5-fluorouracil; C, cyclophosphamide; CDA, cytidine deaminase; DCR3, decoy receptor 3; Gem, gemcitabine; hENT1, human equilibrative nucleoside transporter; H3K4me2, H3K9me2, H3K18ac, modified histones; M, methotrexate; MMC, mitomycin C; MSI, microsatellite instability; STRAP, serine/threonine kinase receptor associated protein; TS, thymidylate synthase). Pubmed search used to populate table: (A) randomized[title/abstract] AND fluorouracil[title/abstract] AND adjuvant[title/abstract] AND marker[title/abstract]; (B) randomized[title/abstract] AND 5-fluorouracil[title/abstract] AND adjuvant[title/abstract] AND expression[title/abstract AND survival[title/abstract]; (C) RTOG 9704.